Low-dose versus high dose radioactive iodine ablation differentiated thyroid carcinoma: a prospective randomized study.

Ibrahim, Dina; Kelany, Mohamed; Michael, Maha M.; Elsayed, Zeinab

doi:10.1200/jco.2016.34.15_suppl.6087

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study recurrence rate was comparable in both groups, in intermediate-risk patients ablated with high and low-dose the recurrence rate was 0% and 03%, respectively ( P = .45), in case of low-risk patients it was exactly the same in both groups 02% ( P = .67). Two clinical research studies 16,17 in 2016 demonstrated equal effectiveness of low- versus high-dose radio-iodine ablation.…”

Section: Discussionmentioning

confidence: 99%

Comparing High and Low-Dose Radio-Iodine Therapy in Thyroid Remnant Ablation Among Intermediate and Low-Risk Papillary Thyroid Carcinoma Patients—Single Centre Experience

et al. 2021

View full text Add to dashboard Cite

The role of Iodine-131 therapy is well established as an adjuvant therapy and for thyroid remnant ablation in differentiated thyroid cancer (DTC); however controversy still exists regarding its appropriate dose. Purpose of this study was to compare the effectiveness of low-dose and high-dose Iodine-131 ablation therapies in low- and intermediate-risk PTC patients. Eighty-four patients were divided equally into Group I: Ablated with high dose of Iodine-131 and Group II: Ablated with low dose of Iodine-131. Iodine-131 WBS, serum TG levels and USG neck of all patients were performed at first presentation, 6 months, 1 year, and 2 years follow up. Results are as follows: Group I: 64%, 72%, and 76% intermediate-risk patients were disease free at the follow up intervals of 6 months, 1 year, and 2 years, respectively. Similarly 70%, 82%, and 82% low-risk patients were disease free at above mentioned intervals. Group II: 56%, 60%, and 64% were disease free among intermediate-risk patients while percentage of disease free low-risk patients was 70%, 76%, and 76% at follow up intervals. Low dose of radioactive Iodine-131 was found as effective as high dose in thyroid remnant ablation of PTC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparing High and Low-Dose Radio-Iodine Therapy in Thyroid Remnant Ablation Among Intermediate and Low-Risk Papillary Thyroid Carcinoma Patients—Single Centre Experience

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In general, the prognosis of well-differentiated thyroid cancers is believed to be excellent, particularly for localized DTC and thyroid cancer with regional lymph node metastases [ 8 ]. To our knowledge, there is only limited research work on prognostic factors and outcomes of DTC, specifically for Middle Eastern and Arab populations [ 9 , 10 , 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Long-Term Survival Analysis and Prognostic Factors of Arabic Patients with Differentiated Thyroid Carcinoma: A 20-Year Observational Study at the King Hussein Cancer Center (KHCC) Involving 528 Patients

Al‐Ibraheem

Al-Rasheed

Mashhadani

et al. 2023

Cancers

View full text Add to dashboard Cite

DTC accounts for the majority of endocrine tumors. While the incidence of thyroid cancer has been increasing globally over the past few decades, papillary thyroid carcinoma (PTC) generally shows an excellent prognosis, except in cases with aggressive clinicopathological features. This study aimed to assess the 5- and 10-year overall survival (OS) and progression-free survival (PFS) of 528 Arabic patients diagnosed with primary DTC from 1998 to 2021. Additionally, the study aimed to analyze the impact of various factors on both OS and PFS. An univariable survival analysis was conducted using Kaplan–Meier curves. The 5- and 10-year OS for patients with DTC have exceeded 95%. Additionally, PFS showed very good rates (ranging between 96.5 and 85% at 5 and 10 years, respectively). Age, male gender, risk of recurrence, and distant metastasis were identified as the main negative prognostic factors for both OS and PFS, while RAI treatment was found to be a significant factor in improving OS. Moreover, adherence to the King Hussein Cancer Center’s (KHCC) CPG demonstrated significant improvement in PFS. These findings highlight common prognostic factors and favorable outcomes in Arabic patients with DTC treated at a tertiary cancer center using standard of care approaches.

show abstract

Neue Aspekte in der Therapie von Schilddrüsenkarzinomen

Lőrincz

Topp

Knecht

2015

HNO

View full text Add to dashboard Cite

At the beginning of June 2015, the Annual Meeting of the American Society of Clinical Oncology (ASCO) took place in Chicago. A total of 24 studies in the field of thyroid oncology were presented, being discussed in the present review article according to the degree of cancer cell differentiation. The leading curative treatment modality is still surgery. Kinase inhibitors are used primarily in the context of palliative treatment concepts. The most recent treatment options in thyroid oncology, both surgical and medical, are summarized in the following article.

show abstract

Low-dose versus high dose radioactive iodine ablation differentiated thyroid carcinoma: a prospective randomized study.

Cited by 4 publications

References 0 publications

Comparing High and Low-Dose Radio-Iodine Therapy in Thyroid Remnant Ablation Among Intermediate and Low-Risk Papillary Thyroid Carcinoma Patients—Single Centre Experience

Comparing High and Low-Dose Radio-Iodine Therapy in Thyroid Remnant Ablation Among Intermediate and Low-Risk Papillary Thyroid Carcinoma Patients—Single Centre Experience

Long-Term Survival Analysis and Prognostic Factors of Arabic Patients with Differentiated Thyroid Carcinoma: A 20-Year Observational Study at the King Hussein Cancer Center (KHCC) Involving 528 Patients

Neue Aspekte in der Therapie von Schilddrüsenkarzinomen

Contact Info

Product

Resources

About